Nickolas Papadopoulos
Fondateur chez Thrive Earlier Detection Corp.
Profil
Nickolas Papadopoulos is associated with two companies, Haystack Oncology, Inc. and Thrive Earlier Detection Corp.
He is the founder of both companies.
At Thrive Earlier Detection Corp., he holds the title of Director starting from 2019.
Haystack Oncology, Inc. does not list any titles associated with Dr. Papadopoulos.
Postes actifs de Nickolas Papadopoulos
| Sociétés | Poste | Début |
|---|---|---|
Thrive Earlier Detection Corp.
 Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Fondateur | 01/01/2019 |
Haystack Oncology, Inc.
 Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | Fondateur | 01/01/2021 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Health Technology |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | Health Services |
